Apricus Biosciences' Executives to Present at Two Upcoming Conferences

Apricus Biosciences' Executives to Present at Two Upcoming Conferences

SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that the Company will present at two upcoming conferences.

Edward Cox, Vice President, Corporate Development, will present at The
BIO-Europe 2012 Conference, being held at the CCH Congress Center in Hamburg,
Germany. Mr. Cox's presentation will take place on Tuesday, November 13, 2012
at 10:00 a.m. Central European Time.

Steve Martin, Interim Chief Executive Officer and Chief Financial Officer will
present at The Lazard Capital Markets 9th Annual Healthcare Conference, being
held at The Pierre Hotel in New York City.Mr. Martin's presentation will take
place on Wednesday, November 14, 2012 at 9:00 a.m. Eastern Time.

The Lazard presentation will be webcast and accessible online at
http://wsw.com/webcast/lz13/apri/ and that presentation, along with the
Bio-Europe presentation, will be available on the Company's website at
www.apricusbio.com.A replay of the webcasts will be available on the
Company's website for 14 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, high-demand therapeutic classes. The Company has four approved
products and has developed a strong pipeline of multiple late-stage product
candidates. With commercial operations in both the U.S. and Europe (France),
Apricus Bio generates revenues and growth from sales of its commercial
products and by out-licensing, in certain territories, its pipeline products
and NexACT^® technology.

Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Takeda, Abbott Laboratories, Sandoz, Warner Chilcott, and Bracco, and
co-promotes multiple products in France.

Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI.

For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.

CONTACT: Apricus Bio Investor Relations:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Apricus logo